Ribonexus appoints David Howat as CDO

Ribonexus SAS
Appointee name
David Howat


David Howat, an experienced pharma research and development manager, has joined Ribonexus SAS of France as chief development officer (CDO). Ribonexus is developing a pipeline of drugs targeting a protein which is associated with a cancer’s resistance to many current therapies. Dr Howat was previously CDO at Haoma Medica Ltd, a UK biotech, and CDO and head of R&D at Evgen Pharma Plc in the UK.

Ribonexus announced the appointment on 9 May 2023.

Copyright 2023 Evernow Publishing Ltd